bluebird bio (BLUE)
(Delayed Data from NSDQ)
$1.05 USD
-0.02 (-1.87%)
Updated May 16, 2024 04:00 PM ET
After-Market: $1.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 361 - 380 ( 530 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of September 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage of BLUE to Mark Breidenbach and reestablishing estimates, a Buy rating and $87 price target
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The A to Z of HSCT: InvestorÂ’s guide to Hematopoietic Transplant Medicine
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Ph 3 HGB-207 Study Opens Under Existing IND, Reiterate OUTPERFORM and $117 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Q2 EPS; Looking Ahead to ASH for Next Major Clinical Update; Reiterate OUTPERFORM and $117 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Q1 EPS; Recent Lenti-D Data in CALD Highlights BLUE''s Platform; Reiterate OUTPERFORM and $117 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology AACR Roundup for Covered Companies.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
So Far, So Good -- Encouraging Interim Update from Ongoing Starbeam Study of Lenti-D in CCALD, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Sickle Cell Expert Shares His Views on Current and Future Therapies
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q15 Results; Interim Look at CCALD Data in April, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals - ASH Recap 2015
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Loss of Expression Is the Concern - Lowering Rating to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E